跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
OGIVRI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
OGIVRI
Authorized
STANDARD
OGIVRI
Biosimilar Collaborations Ireland Ltd.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
91bfa50d77fc7432
Company
Biosimilar Collaborations Ireland Ltd.
Type
Standard
Approval Details
Approval Id
91bfa50d77fc7432
Drug Approval Canada Name
OGIVRI
Product Name
OGIVRI
Status
Marketed
Status Date
2023-12-18
Original Market Date
2019-06-06
Din
02474425
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FD01 TRASTUZUMAB
Atc Name
l 01 fd 01
Aig Number
0154252002
Company Name
Biosimilar Collaborations Ireland Ltd.
Company Address
UNIT 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Dublin, --, Ireland, D13R20R
Company Detail Path
/organization/biosimilar-collaborations-ireland-ltd
Company Information
Pharmaceutical Company Name
Biosimilar Collaborations Ireland Ltd.
Country Name
Ireland
Active Ingredients
TRASTUZUMAB
150 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
91bfa50d77fc7432
Type
Standard
Back to Health Canada Approvals